Robert G. Maki
罗伯特·马基
MD, PhD
Professor of Medicine; Director, Sarcoma Program
👥Biography 个人简介
Robert G. Maki, MD, PhD is Professor of Medicine and Director of the Sarcoma Program at the University of Pennsylvania Perelman School of Medicine. He is one of the most prominent sarcoma oncologists in the United States, recognized for his contributions to the clinical development of novel systemic therapies for soft tissue and bone sarcomas. His research spans phase I–III clinical trials, tumor biology, and translational studies aimed at identifying druggable targets in rare mesenchymal malignancies. Dr. Maki has been a leading investigator in studies evaluating trabectedin, pazopanib, and combination immunotherapy approaches in sarcoma subtypes. He has served in leadership roles at major cooperative oncology groups and is a past chair of the Sarcoma Disease Committee at ECOG-ACRIN, where he has shaped the national clinical trials portfolio for sarcoma. He is widely recognized as a mentor and educator and has authored more than 200 peer-reviewed publications on sarcoma biology and treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Trabectedin in Soft Tissue Sarcoma
Led and participated in pivotal US trials of trabectedin (Yondelis) for liposarcoma and leiomyosarcoma, contributing to the evidence base supporting FDA approval of trabectedin for these histologies and defining its role in the treatment sequence for translocation-associated sarcomas.
Pazopanib in Non-Adipocytic Soft Tissue Sarcoma
Contributed to the PALETTE phase III trial and related translational analyses establishing pazopanib as an approved treatment for non-adipocytic soft tissue sarcoma following prior chemotherapy, expanding available targeted therapy options.
GIST Biology and Imatinib Resistance Mechanisms
Conducted foundational studies on the molecular biology of gastrointestinal stromal tumor (GIST) and secondary KIT/PDGFRA resistance mutations, informing the development of later-line therapies including sunitinib and regorafenib.
National Sarcoma Clinical Trials Leadership
Served as Sarcoma Disease Committee chair at ECOG-ACRIN, overseeing the design and execution of nationally coordinated clinical trials, and co-authored widely cited NCCN guidelines for soft tissue sarcoma management.
Representative Works 代表性著作
Trabectedin in Unresectable or Metastatic Liposarcoma and Leiomyosarcoma
Journal of Clinical Oncology (2015)
Phase III T-DIS trial demonstrating that trabectedin significantly improved progression-free survival versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma, supporting FDA approval.
Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE)
The Lancet (2012)
Landmark phase III trial demonstrating that pazopanib significantly prolonged progression-free survival versus placebo in patients with non-adipocytic advanced soft tissue sarcoma after prior chemotherapy.
Molecular subtypes and clinical outcomes in soft tissue sarcoma
Journal of Clinical Oncology (2010)
Comprehensive translational analysis linking molecular subtype classification of soft tissue sarcomas to chemotherapy response and clinical outcomes, establishing a framework for histotype-stratified treatment.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 罗伯特·马基 的研究动态
Follow Robert G. Maki's research updates
留下邮箱，当我们发布与 Robert G. Maki（University of Pennsylvania, Perelman School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment